Design of selective eglin inhibitors of HCV NS3 proteinase
Research article published in Biochemistry (1998)
Abstract
Hepatitis C virus (HCV) infection is a major health problem that leads to cirrhosis and hepatocellular carcinoma in a substantial number of infected individuals, estimated to be 100-200 million worldwide. Unfortunately, immunotherapy or other effective treatments for HCV infection are not yet available, and interferon administration has limited efficacy. Different approaches to HCV therapy are being explored, and these include inhibition of the viral proteinase, helicase, and RNA-dependent RNA polymerase and development of a vaccine. Here we present the design of selective inhibitors with nanomolar potencies of HCV NS3 proteinase based on eglin c. These eglin c mutants were generated by reshaping the inhibitor active site-binding loop, and the results emphasize the role played by residues P5-P4' in enzyme recognition. In addition, alanine scanning experiments provide evidence that the N terminus of eglin c also contributes to NS3 binding. These eglin inhibitors offer a unique tool for accurately assessing the requirements for effective inhibition of the enzymatic activity of NS3 and at the same time can be considered lead compounds for the identification of other NS3 inhibitors in targeted design efforts.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
Peer-reviewed clinical and outcomes research relevant to medicinal leech therapy and its biology. Indexed in PubMed and verified against the NCBI record.
Why This Matters for Hirudotherapy
This protein-engineering study reshaped the active-site-binding loop of eglin c to create selective, nanomolar-potency inhibitors of the hepatitis C virus NS3 proteinase, with alanine scanning showing the inhibitor's N-terminus also contributes to NS3 binding, and the authors frame these mutants as lead compounds and tools for designing further NS3 inhibitors. The relevance to ASH is that eglin c is a small protease-inhibitor scaffold derived from the medicinal leech Hirudo medicinalis, and this work exemplifies the leech-secretome-as-drug-discovery-platform narrative, showing how a leech-derived inhibitor can be re-engineered to hit a wholly different therapeutic target. Honest caveat: this is purely in-vitro inhibitor design against a viral enzyme, not a study of leech therapy, anticoagulation, or any clinical/HCV treatment outcome, and the engineered molecules are described as research leads, not approved drugs.
Citation
Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026